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ABSTRACT 
Dry Eye Disease (DED) is a chronic disease that diminishes the quality of life (QOL) of 
millions of Americans. Clinical tests of DED poorly correlate with patient-reported symptoms, 
and current dry eye questionnaires that include QOL measures require considerable time and 
effort to complete. Therefore, as part of a research team in the University of North Carolina 
(UNC) Ophthalmology Department, I helped develop a single-item, patient-reported dry eye 
scale that conveys both the patient’s dry eye symptoms and the effects of these symptoms on 
the patient’s quality of life. Our initial questionnaire development consisted of two phases: 
conceptualization and questionnaire development and cognitive interviewing and questionnaire 
modification. During phase one, we performed an extensive literature review and consulted 
multiple patients and experts to create the conceptual framework for our dry eye questionnaire. 
During phase 2, we administered this preliminary questionnaire to multiple dry eye patients; 
then, using cognitive interviewing techniques, we asked these patients several questions about 
the questionnaire. In total, 18 patients were interviewed, and their input led to further 
modifications of our dry eye scale and ultimately led to the final product: the UNC Dry Eye 
Management Scale (UNC DEMS). Validity and reliability testing of this dry eye scale are 
ongoing, but early statistical analyses indicate that the UNC DEMS is a valid patient-reported 
measure of both symptoms and QOL in DED. Our hope is that this tool will assist both clinicians 
and patients in the monitoring and management of DED in the time-constricted clinical setting. 
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INTRODUCTION 
Dry eye disease (DED) is a common ocular disease with a prevalence of 5-17% in the 
United States.1-3 The disease affects approximately twice as many women as men, and disease 
prevalence increases with age.1 DED is a chronic disease characterized by many different 
symptoms including ocular pain, grittiness, burning, foreign body sensation, tearing, and 
photophobia.4,5 Multiple studies have confirmed that the disease diminishes a person’s quality of 
life (QOL).1,5-9 Specifically, DED symptoms can impede patients’ abilities to read, use a 
computer, drive, and perform basic work activities.1 In addition, a recent study has shown that 
DED’s negative effects on QOL increase as disease severity increases from mild to moderate to 
severe and can ultimately lead to individuals missing work due to the severity of their 
symptoms.9  
Two recent utility assessments compared DED with several other chronic conditions 
known to diminish QOL. Utility assessments often use the time trade-off method (TTO) in which 
patients are provided their current life-expectancy in years and asked how many years they 
would be willing to give up to be free from a given disease or condition.3,10 For example, in the 
case of DED, a patient may be asked “Would you rather live 30 years with dry eye or 25 years 
totally cured from dry eye?” The question is repeated with years gradually decreasing for the 
disease-free option until the patient selects living with the disease for his or her full life 
expectancy. The fewest number of years the patient is willing to live in order to live disease-free 
is then divided by the initial life expectancy to produce the final utility score.3,10 Although these 
utility scores are useful in and of themselves, studies have shown that lower utility scores also 
correlate with worse QOL.3 In the aforementioned utility assessments, scores calculated for 
moderate to severe dry eye ranged from 0.58 to 0.86 and were similar to (and in some cases 
lower than) the utility scores of other chronic conditions such as dialysis, severe angina, and hip 
fractures.3,10 These low utility scores clearly indicate how severely DED can diminish QOL.  
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BACKGROUND AND SIGNIFICANCE 
Despite the increasing evidence that DED diminishes QOL, only two patient-reported dry 
eye questionnaires specifically assess QOL in patients who have DED: the Ocular Surface 
Disease Index (OSDI)11 and the Impact of Dry Eye on Everyday Life (IDEEL).4,6,12 These two 
questionnaires have proven particularly valuable in clinical trials.2,4-6,8,9,13 The overall dearth of 
DED questionnaires that include QOL assessment, however, is concerning considering the 
weak correlation between clinical measures of dry eye disease and patient-reported 
symptoms.4,6,7 The small correlation between physician and patient assessment of severity of 
DED in the clinic further highlights the need for reliable patient-reported measures of QOL in 
DED patients.3 The US Food and Drug Administration (FDA) has recently emphasized the 
necessity of using QOL measures and other patient-reported outcome measures (PROs) to 
monitor treatment efficacy.5 In 2006, the FDA published guidelines for the proper instrument 
development of these PROs—including recommendations such as forming a conceptual 
framework, performing reliability and validity testing, and involving patients in instrument 
development.14 This is only a small indication of the growing paradigm favoring patient-reported 
outcomes in policy, health system models of delivery, and even reimbursement. Other federal 
agencies have also increased their emphasis on PROs; for example, the National Institutes of 
Health (NIH) developed the Patient-Reported Outcomes Measurement Information System 
(PROMIS) in 2004 to provide an online resource to assist in the development of reliable PRO 
measures and questionnaires.15 All these factors drive the goal of this research study: To 
produce a patient-centered, patient-reported dry eye scale that conveyed both the patient’s dry 
eye symptoms and the effects of those symptoms on the patient’s quality of life. 
METHODS 
 The initial instrument development of the University of North Carolina Dry Eye 
Management Scale (UNC DEMS) consisted of 2 phases—conceptual development of the scale 
and modification of the scale guided by cognitive interviewing of patients with DED.  
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Phase I: Conceptualization and Questionnaire Development  
 After performing a preliminary literature search on dry eye questionnaires, I and other 
members of the research team commenced the initial phase of our research, gathering expert 
and patient opinion for the development of the UNC DEMS. This phase took place from August 
– November, 2013. For expert opinion, our research team consulted multiple ophthalmology 
attendings, residents, and medical students in the UNC Department of Ophthalmology. In 
addition, I and one other team member consulted a university biostatistician (Ph.D.) and a 
residential expert in survey and instrument development (Ph.D.). The research team presented 
the basic concept of developing a simplified dry eye scale that could accurately report both 
patient symptoms and the effect of those symptoms on quality of life to our contributing experts. 
We then asked for feedback in three areas: the feasibility of the scale, recommendations on 
what to include in the questionnaire, and finally the clinical appeal of the questionnaire.  
 In addition to consulting experts, we also sought input from patients with DED. An 
ophthalmologist on the research team directly asked multiple patients with DED what their 
primary symptoms were and how those symptoms affected their daily life. The ophthalmologist 
also asked the patients to select a number on a scale of 1 to 10 that would best simultaneously 
describe their DED symptoms and the effect of DED on their overall quality of life (QOL).  
 We combined the data gathered from expert and patient opinion with data already 
acquired from our extensive literature search on DED questionnaires. A preliminary version of 
the UNC DEMS was then created to be administered in Phase II of the study (Figure 1).  
Phase II: Cognitive Interviewing and Questionnaire Modification 
 After the initial questionnaire was developed, one other member of the research team 
and I, both of whom had been trained in cognitive interviewing, administered the UNC DEMS 
and the OSDI to 18 patients with DED and subsequently performed cognitive interviewing on 
those patients. This phase took place from December, 2012 – January, 2013. We selected a 
broad range of subjects in order to include an adequate representation of women and men, 
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many races, people of different ages, and people with different severity of DED. Patients were 
generally recruited in the clinic prior to their scheduled ophthalmology appointment.  
After completing the UNC DEMS and the OSDI, patients were asked multiple questions 
by the interviewers about the UNC DEMS. Some examples of questions asked include the 
following: 
 “What do you think the question is asking about?” 
 “I asked you to use a 1 to 10 scale. Can you describe what you are thinking of when you 
think of a 1? [Pause for patient to answer] And what about the 10—what are you thinking 
of? [Pause for patient to answer] What about the middle? What are you thinking of when 
you think of the 5?” 
 “People usually say the symptoms of dry eyes are pain, burning, grittiness, ‘feeling like 
something’s in your eye’, tearing, and sensitivity of light. I’d like to take each of these, 
and ask what they mean to you. First, let’s start with pain. How does pain from dry eyes 
feel to you?” [repeat question for the remaining five symptoms] 
 “In the questionnaire, we asked about how your dry eye symptoms affected your daily 
life. What does daily life mean to you?” 
 “When you picked a number on the scale, were you thinking more about the dry eye 
symptoms, the effect on your daily life, or both?” 
 “Does this scale let you say how good or bad your eyes are feeling?” 
 
We recorded patient responses to cognitive interviewing and used this patient input to 
guide the modification of the UNC DEMS. The first 7 subjects completed the initial UNC DEMS 
(Figure 1). The subsequent subjects received a modified version of the UNC DEMS. All patients 
were asked similar cognitive interviewing questions irrespective of which questionnaire they 
received. Subject responses ultimately guided the creation of the final version of the 
questionnaire (Figure 2).  
Statistical Analysis: 
 Pearson’s correlation coefficient was used to assess for the degree of correlation 
between subjects’ UNC DEMS scores and OSDI scores. I calculated two Pearson correlation 
coefficients. The first correlation compared the scores of all 18 subjects who had completed the 
OSDI and any version of the UNC DEMS. The second correlation compared the OSDI and UNC 
DEMS scores of the last 10 subjects who had completed the finalized version of the UNC 
DEMS. 
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RESULTS 
Phase I: 
 Our initial literature search provided us examples of symptoms and disease effects on 
QOL to ask about in our questionnaire. Consulting experts provided feedback that developing a 
scale that measured DED symptoms and the effect of DED on QOL was feasible and had 
strong clinic appeal, as it could be used not only to monitor patient disease but also to educate 
patients on the management of their disease. In addition, experts provided recommendations of 
what to include in the scale. Although most symptoms in our scale came from our literature 
search, several experts noted that some patients may not understand the phrase “foreign body 
sensation” (a term used by opthalmalogists but not, most of the time, by patients); therefore, 
“feeling like something’s in your eye” was used in its place. For similar reasons, the phrase 
“daily life” was used to represent “quality of life.”  
 Patients consulted in Phase I confirmed our selection of dry eye symptoms and 
examples of daily life to be included in the scale. Patients also had no difficulty in selecting a 
number on a scale of 1-10 to describe both their symptoms and the effect of those symptoms on 
their QOL. Combining the information from our literature search with data gathered from expert 
and patient consultation, we created an initial version of the UNC DEMS (Figure 1) to be used 
in Phase II of our study.  
Phase II:  
 Of 19 patients recruited, 18 agreed to participate in our study. Basic demographic 
information of the patients interviewed in Phase II is provided in Table 1. In general, patient 
responses from the cognitive interviewing process indicated that patients understood and liked 
the new UNC DEMS questionnaire. Responses from the first seven patients interviewed, 
however, also indicated that patients were selecting a number based on the examples of daily 
life provided in the tags underneath the number scale rather than based on symptom severity 
and overall effect on quality of life. Most patients stated that they were thinking about both their 
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dry eye symptoms and the effect on their daily life when answering the question; upon further 
probing, however, patients indicated that they were selecting their number score based on the 
examples of daily life provided in the tags underneath the numbers on the scale. This method of 
number selection resulted in a clustering of scores around the middle of the scale, as this is 
where the initial questionnaire started listing examples of effects on daily life. This subject 
feedback convinced us to move the examples of daily life from the tags underneath the numbers 
to the main text of the questionnaire.  
 Other modifications of the scale were more minor in nature but still important. For 
example, several patients thought that the term “severe” was more appropriate only for a score 
of 9 or 10 on the scale rather than a score of 7 or 8. Thus, we changed the term describing 
symptom severity in the 7-8 tag from “severe” to “very bothersome.” Some patients had also 
mentioned hobbies as an example of daily life affected by DED; therefore, we added the phrase 
“doing things you enjoy” as an example of daily life. 
 After we completed these modifications, we gave the modified UNC DEMS to  11 more 
patients, whom we subsequently interviewed (Note: Patient 8 was given a scale that included 
only some of the modifications listed above). Although minor grammar corrections were made 
following Patient 11’s interview, Patients 9-18 received essentially the same final version of the 
scale (Figure 2). Subject interview responses indicated these latter patients selected their UNC 
DEMS number scores based on symptom severity and the overall effect of DED on their quality 
of life, as was our initial intention for the scale. In addition, when asked “Do you feel that the 
term ‘very bothersome’ matches a 7-8 on the scale?”, patients responded affirmatively. Subjects 
also approved of the inclusion of “doing things you enjoy” as one of the examples of daily life.  
 After all 18 patients were interviewed, the research team added one supplemental 
question to the UNC DEMS. Underneath the scale, we added “Is there anything else you would 
like your doctor to know about your eyes?” followed by a blank space (Figure 3). The reason for 
this additional question was that, during the cognitive interviewing process, one patient wrote 
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additional information about his dry eye symptoms directly onto the UNC DEMS questionnaire. 
Another patient indicated that he liked the UNC DEMS questionnaire but wanted to be able to 
discuss the details of his DED with his ophthalmologist. Therefore, this supplemental question 
was placed underneath the scale of the UNC DEMS to serve as a springboard for discussion 
with the physician about a patient’s DED. 
Statistical Analysis: 
 Questionnaire scores for all 18 patients showed a high degree of correlation between the 
UNC DEMS and OSDI scores (Pearson’s correlation coefficient = 0.744, 95% CI = 0.426, 0.899, 
p-value < 0.001). The UNC DEMS and OSDI scores for the last 10 patients, who received the 
final version of the UNC DEMS, produced an even slightly higher degree of correlation 
(Pearson’s correlation coefficient = 0.789, CI = 0.317, 0.948, p-value = 0.007).  
DISCUSSION 
The early phases of our research indicate that the UNC DEMS will help meet the 
growing need for valid, reliable, and low-burden patient-reported measures for DED. As it was 
developed with input from both DED experts and patients, the UNC DEMS is simultaneously a 
clinically based and patient-centered questionnaire. Although some may critique the UNC 
DEMS for being essentially a single-item visual analog scale (VAS), a recent study found that 
the single-item EuroQoL VAS was better able to distinguish between different severity levels 
(e.g. mild, moderate, severe) of DED  than was any component of the Medical Outcomes Study 
Short Form 36 Health Survey (a general health status QOL measure).2 As the UNC DEMS 
combines a VAS with specific dry eye symptoms and effects on QOL, one would expect it to be 
even more discriminative than the EuroQoL VAS. Our questionnaire’s high correlation with 
OSDI scores support this claim.   
Another potential critique of our instrument development would be that the UNC DEMS 
offers no new advantages over the IDEEL and OSDI questionnaires. Although both of these 
latter instruments are valid and reliable measures of DED’s effects on a patient’s daily living, 
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both are also multi-item questionnaires that may be burdensome for patients to complete and 
that consume valuable clinic time to score.11-13 The UNC DEMS offers clinicians a single-item 
questionnaire which, based on our cognitive interviews, is easily read, understood, and 
completed by patients. Even though scores on the UNC DEMS and OSDI were highly 
correlated, the UNC DEMS is not a replacement for either the OSDI or IDEEL. Both of these 
questionnaires are and will likely remain valuable patient-reported measures in the clinic and in 
clinical trials.2,4-6,8,9,13 The UNC DEMS instead offers an alternative or supplemental 
questionnaire for clinical trials and in particular for clinical practice. It may prove particularly 
useful as an efficient disease-monitoring tool when time is limited in the clinic. 
Current therapies for DED include artificial tears, anti-inflammatory treatments (including 
corticosteroids and cyclosporine ophthalmic emulsion 0.05% [Restasis: Allergan Inc.]), punctal 
plugs, antibiotics, and other etiology-specific treatments (e.g. lid hygiene and surgical 
procedures, among others).5,12 Although beneficial to some, DED therapies are of limited benefit 
to many patients—in particular patients with moderate-to-severe DED.2,12 As dry eye symptom 
improvement in response to treatment does not correlate strongly with clinical dry eye tests, it is 
imperative that valid, efficient patient-reported measures be developed and used to monitor 
disease treatment and management.4-7,13 Our research indicates the UNC DEMS is a valid, 
efficient patient-reported measure that could be used for such purposes. 
In addition to being a potential tool for monitoring treatment, the UNC DEMS offers hope 
for better educating patients about the chronic nature of their disease. DED is a chronic disease 
that not only reduces QOL but also harms individuals’ moods and confidence in moderate-to-
severe disease.5 The UNC DEMS is specifically designed as a single-item questionnaire 
physicians can use to educate their patients on the chronic nature of their disease as well as the 
treatment goals of DED—goals that are palliative rather than curative.4,5,12 The final phase our 
research (pilot and feasibility testing) is specifically designed to assess the UNC DEMS’s 
usability in this educational context. Our hope is that using the UNC DEMS as not only a 
9 
 
disease-monitoring tool but also as a patient-education tool will provide patients a better 
understanding of their disease and subsequently lead to increased confidence in their ability to 
manage their dry eye.  
One final advantage of the UNC DEMS is that it includes a time frame. Many dry eye 
surveys neglect to include any type of time frame, which in turn could lead to a wide variation in 
patient responses depending on whether they are trying to report current symptoms, average 
symptoms, or most severe symptoms. This lack of a time reference could also help explain the 
discrepancies between patient-reported symptoms and clinical findings.4 The one week time 
frame in the UNC DEMS provides a reference point that allows patients to account for the 
fluctuations in their symptom severity while also covering a small enough period of time that 
patients can easily recall their symptoms and the overall effect on their QOL.   
Our study is not without limitations. First, our sample consisted of only 18 patients. While 
this size could certainly limit the value of our statistical analysis, this number of patients is 
considered more than adequate for cognitive interviewing.16 In addition, we included a wide 
variety of patients representative of multiple races and both sexes in order to ensure utility of 
this instrument in a diverse population. Since we did use such a small sample size for our 
statistical analysis, we are currently performing further testing on the UNC DEMS with a much 
larger sample size to ascertain the characteristics of the UNC DEMS’s validity and reliability. 
One other limitation of our study is that it was performed solely at the UNC Ophthalmology 
Clinic. Although the patient population at UNC is very diverse, our institution-specific research 
does potentially limit the generalizability of our questionnaire. Once the UNC DEMS has 
undergone further validity testing at UNC, other researchers should perform trials at their 
respective institutions to test for broader generalizability of this tool.  
Continued research on the UNC DEMs is ongoing. Currently, a mid-sized validity and 
repeatability trial is being performed at UNC. This will be followed by a pilot and feasibility trial 
testing whether the UNC DEMS is a useful tool for educating patients about the chronic nature 
10 
 
and management of DED. Despite the need for this future research, our initial study results 
show that the UNC DEMS is a valid patient-reported measure of both symptoms and QOL in 
DED. Our hope is that this tool will assist physicians in the monitoring and management of dry 
eye patients in their time-limited clinical settings. 
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Table 1: Patient Demographics 
Patient Demographics 
Sex (%) 
     Male (50%) 
     Female (50%) 
 
Mean Age in Years (range) 
     65 (47 – 90) 
 
Race (%) 
     Caucasian (72%) 
     African-American (17%) 
     Other (11%) 
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Figure 1: Original UNC DEMS 
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Figure 2: Modified UNC DEMS 
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Figure 3: Final UNC DEMS with Supplemental Question 
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APPENDIX A: Systematic Review 
A Systematic Review of Quality of Life Measures in Dry Eye Questionnaires  
INTRODUCTION 
The evidence that dry eye disease (DED) can greatly diminish individuals’ quality of life 
(QOL) is steadily increasing.1-3 Recent utility assessments of DED show that moderate-to-
severe dry eye can cause a similar decrease in QOL as dialysis, severe angina, and disabling 
hip fractures.4,5 Several clinical dry eye tests exist to help monitor the severity of DED. For 
example, fluorescein staining can help highlight damage to the corneal epithelium caused by 
persistent dry eye, and tear break-up time can be used to monitor tear film stability. Multiple 
other tests exist such as lissamine green staining, Schirmer test type 1, Schirmer test type 2, 
and many other clinical measures.1,6,7 Unfortunately, these tests correlate extremely poorly with 
patient symptoms and QOL measures in dry eye patients.1 This weak correlation makes 
assessing QOL through patient-reported questionnaires even more important.8,9 In addition, the 
Federal Drug Administration (FDA) has increased their emphasis on properly developing and 
using patient reported outcomes (PROs), such as QOL measures, in clinical drug trials to 
determine treatment efficacy.10 Due to this increased emphasis on proper PRO development, as 
part of the instrument development of the UNC Dry Eye Management Scale (DEMS), a novel 
PRO questionnaire for DED, I performed a systematic review to determine what other dry eye 
questionnaires include QOL measures in their assessment of DED. 
METHODS 
The main objective of this systematic review was to determine which validated, reliable 
dry eye questionnaires include QOL measures in their assessment of PROs. To answer this 
question, I performed a PubMed search on March 9, 2013, using the following Medical Subject 
Headings (MeSH) phrases (results provided in parentheses):  
 “dry eye questionnaire AND quality of life” (107 articles) 
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 “dry eye scale AND quality of life” (31 articles)  
 “dry eye AND quality of life assessment” (46 articles) 
 “dry eye AND quality of life measures” (42 articles) 
 “dry eye AND quality of life measurement” (15 articles) 
These 241 articles were subsequently pulled into a research database for review. Of 
these articles, 101 were duplicates and removed from the database. The remaining 140 articles 
underwent full title and abstract review. For articles to be included in the final analysis, the 
articles had to assess dry eye questionnaires that included QOL measures, be written in 
English, and be published prior to March 9, 2013.  In addition, the questionnaires assessed by 
these articles had to be written in English and not limited to a specific autoimmune disorder (e.g. 
Grave’s Disease).  Of the 140 articles undergoing abstract review, 122 articles were eliminated 
as they did not meet eligibility criteria.  
The remaining 18 articles underwent full-text review. During this phase, I eliminated one 
article due to its focus solely on an autoimmune-specific questionnaire.11 I eliminated one other 
article because it did not discuss any dry eye questionnaires.12 The remaining 16 articles 
provided the basis for this review.1-6,8,9,13-20 The references of these 16 articles were also 
examined to uncover more background information on the validity and reliability of specific dry 
eye questionnaires when necessary—a process that led to four more articles being used for this 
review.7,21-23 Finally, if the actual questionnaires were not provided in the articles, they were 
procured online or from the UNC Department of Ophthalmology when possible.24-26 
RESULTS 
 Based on this review, two validated, reliable dry eye questionnaires that including QOL 
measures are currently available for clinic use: the Ocular Surface Disease Index (OSDI) and 
the Impact of Dry Eye on Everyday Life questionnaire (IDEEL).1,7,13,24 Other dry eye 
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questionnaires also assess some degree of QOL but have either not been tested for validity and 
reliability or are limited in what QOL measures they assess. 
The OSDI 
Description: The OSDI is a 12-item questionnaire that assesses both dry eye symptoms and 
their effects on vision-related functioning over the past week. It contains 3 subsections including 
vision-related function, ocular symptoms, and environmental triggers.7-9 Patients are asked 
about the frequency of various symptoms and difficulty with vision-related activities and respond 
on a 0-4 scale that ranges from “none of the time” to “all of the time.” The final score is 
calculated by multiplying the sum of all the scores by 25 and then dividing the total by the 
number of questions answered.7 Scores range from 0 to 100 with 0-12 representing normal dry 
eye disease (DED), 13-22 mild DED, 23-32 moderate DED, and >33 severe DED.7,18 
Validity and Reliability Testing: The OSDI has undergone substantial validity and reliability 
testing since its initial development.7,8 The OSDI as a whole and its three subscales individually 
are all internally consistent and display good-to-excellent test-retest reliability.1,7 Although the 
questionnaire is only weakly correlated with clinical dry eye tests, it is strongly correlated with 
several other dry eye questionnaires and has moderate correlations with artificial tear usage.7 
The scale is capable of accurately discriminating between normal, mild-to-moderate, and severe 
dry eye disease.8 In addition, a minimal clinically important difference (MCID) has been 
determined for mild-to-moderate disease (4.5 – 7.3) and severe disease (7.3 – 13.4).1,8,18 
QOL Measures: The main QOL measures in the OSDI are in its vision-related function 
subscale. This subscale consists of 6 questions which assess the frequency of problems with 
vision and vision-related activities such as reading, watching TV, driving, and using a computer 
or ATM-machine.6,24 These 6 questions are included in the overall OSDI score and can be 
computed into their own vision-related function subscale score as well.7 
Limitations: One limitation of the OSDI is that it only includes some dry eye symptoms such as 
grittiness, sensitivity to light, and pain but does not include other symptoms such as foreign 
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body sensation and tearing.13,24 It also only discusses some of DED’s effects on vision-related 
functioning; therefore, it may not capture the entire effect of DED on a patient’s daily living.13 In 
addition, OSDI responses are limited to measures of frequency (rather than frequency and 
severity).16 A second limitation of the OSDI is the effort required to complete and score the 
scale, which may consume valuable clinic time in a practice.19 
Overall Utility: Overall, the OSDI is a valid, reliable dry eye questionnaire that at least partially 
captures DED’s effects on QOL. Even with its limitations, the OSDI has proven to be a valuable 
patient-reported outcome (PRO) measure in clinical trials as well as ophthalmology clinics.7-9   
The IDEEL 
Description: The IDEEL is a 3-module questionnaire with 57 questions that assesses dry eye 
symptoms, DED’s effect on QOL, and treatment satisfaction over the past 2 weeks.6,13,20 The 
three modules consist of six scales which are outlined below: 
 Dry Eye Impact on Daily Life: Activity Limitations, Work Limitations, and Emotional 
Impact 
 Dry Eye Treatment Satisfaction: Satisfaction with Treatment and Treatment-Related 
Inconvenience 
 Dry Eye Symptom(-Related) Bother (which is its own scale)1,13 
Each module is scored from 0 – 100. Higher scores on the Impact on Daily Life module and 
Treatment Satisfaction module indicate better QOL and higher treatment satisfaction. Higher 
scores on the Symptom Bother module indicate more bothersome dry eye symptoms.13 For the 
Symptom Bother module, 40.0 (± 7.5) is the average score of patients with mild DED, 50.6 (± 
11.0) for patients with moderate DED, and 64.3 (± 8.0) for patients with severe DED.8  
Validity and Reliability: The IDEEL meets the new FDA PRO instrument development guidelines 
and has undergone significant validity and reliability testing.13 In addition, content validity has 
been confirmed by strong evidence of item saturation (i.e. multiple interviews confirmed that the 
questionnaire included the relevant questions needed to achieve its assessment objective).8,13 
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The questionnaire is internally consistent and has good test-retest reliability.8 The IDEEL weakly 
correlates with clinical dry eye tests and generic QOL questionnaires (Short Form-36 [SF-36] 
and EuroQoL-5D [EQ-5D]). In addition, its modules have mild-to-strong correlations with the Dry 
Eye Questionnaire (DEQ).13,14 The Symptom Bother and Impact on Daily Life modules are able 
to discriminate between mild, moderate, and severe DED.3,8 In addition, a MCID of 12 points 
has been determined for the Symptom Bother module.15 
QOL Measures: The IDEEL has an entire module dedicated to assessing DED’s effects on a 
patient’s QOL. The Impact on Daily Life module consists of 31 questions that assess DED’s 
effects on a patient’s emotions (e.g. irritability, sadness), activities (e.g. driving, doing close 
work), and work (e.g. difficulty concentrating, feeling distracted).13 These 31 questions ultimately 
produce a score for the entire Impact of Daily Life module.13 Finally, the IDEEL’s Impact on 
Daily Life and Symptom Bother modules are better able to discriminate between mild, moderate, 
and severe DED than other QOL questionnaires such as the SF-36 and EQ-5D.14 
Limitations: The primary limitation of the IDEEL is that it takes approximately 30 minutes to 
complete the entire questionnaire.1 This limitation is partially offset by the fact that individual 
modules can be used in practice rather than the entire questionnaire.9 One final limitation of the 
IDEEL is that it must be purchased for use.9 
Overall Utility: The IDEEL is a valid, reliable dry eye questionnaire that does an excellent job of 
assessing DED’s effects on QOL. It contains the most QOL measures of any current dry eye 
questionnaire. Its overall utility is somewhat uncertain due to its recent development and thus 
limited use in recent clinical trials, but it holds promise at being an important PRO questionnaire 
for measuring QOL in patients with DED.6,9 In addition to cost, the major limitation of this 
questionnaire’s use in practice may be that it is time-consuming. This limitation, however, may 
not be as restricting in clinical trials.  
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Other Questionnaires:  
 Although the OSDI and IDEEL are the only two disease-specific, validated, reliable 
questionnaires that assess DED’s effect on QOL, other questionnaires have been used to 
assess QOL measures in patients with DED. The 25-item National Eye Institute Visual Function 
Questionnaire (NEI-VFQ-25) assesses the effect of various eye diseases on QOL.9,25 It is not 
disease-specific but has been tested in dry eye patients and displays a modest to strong 
correlation with the OSDI.4,5,8,9,16 Of particular note, the NEI-VFQ-25’s ocular pain subscale had 
the strongest overall correlation with the OSDI leading some researchers to suggest that 
patients with low ocular pain scores on the NEI-VFQ-25 should undergo further dry eye 
testing.16,17 Limitations of the NEI-VFQ-25 for assessing QOL in dry eye patients is that it is not  
disease-specific, needs further validity and reliability testing in a dry eye population, lacks a 
specified recall period, and requires 10-minutes to administer the questionnaire.8,9  
 The original DEQ and the contact lens DEQ (CLDEQ: includes extra questions for 
contact-lens wearers) include questions about DED symptoms effecting daily activities; but 
overall, both questionnaires (as well as subsequent variations of these questionnaires) include 
very few QOL measures and need reliability testing.8,22,26 The Texas Eye Research and 
Technology Center Dry Eye Questionnaire (TERTC-DEQ) is a 33-item questionnaire based on 
the original DEQ that adds several components to the original DEQ, including two questions on 
the disease-effect on QOL.8,21 The questionnaire has undergone some validity testing and can 
discriminate between normal patients and patients with moderate dry eye. Limitations of the 
questionnaire for measuring QOL in dry eye patients include the need for further test-retest 
reliability testing.  In addition, only a small portion of the questionnaire is dedicated to QOL 
measures.21 Thus, all three of these questionnaires are fairly limited in their ability to assess 
DED’s effect on QOL.  
 Several other dry eye questionnaires reported in the literature include QOL measures. 
First, an 11-Question Dry Eye Syndrome Questionnaire including DED-specific QOL questions 
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was used among participants in the Women’s Health Study and Physicians’ Health Study to 
determine the effects of dry eye on daily living.2 Second, a Single Item Score Dry Eye 
Questionnaire (SIDEQ) that attempts to quantify dryness-caused discomfort was used in a 
recent study to determine whether or not dry eye patients were currently symptomatic; this 
questionnaire showed strong correlations with the OSDI as well as some clinical tests.8,23 Both 
of these questionnaires may assess some QOL measures in dry eye patients but are poorly 
described in the literature and need to undergo substantially more validity and reliability testing 
before being recommended for clinical use.2,8  
 One final DED questionnaire that measures QOL is the Ocular Surface Disease 
questionnaire (OSD). It did not meet the criteria for this review because it was developed and 
tested in the French language.8 It includes four modules one of which is quality of life (OSD-
QoL). The OSD-QoL module has been clinically validated and displays low-to-excellent internal 
consistency and test-retest reliability.8 Its main limitations include the need for further validity 
and reliability testing of the other modules (medical management/history, symptoms, and 
treatment satisfaction), lack of data about testing and use in the English language, and no recall 
period provided in the questionnaire.8 Once these limitations are addressed, the OSD may 
serve as valuable tool in the clinic.8 
CONCLUSION: 
This review provides a brief analysis of the dry eye questionnaires currently available to 
assess vision-related QOL in patients with DED and should assist clinicians and researchers 
alike in determining which questionnaire is best for their individual situation such as a clinical 
practice or a clinical trial. To summarize, there are two validated, reliable disease-specific 
questionnaires that assess QOL measures in patients with DED: the OSDI and IDEEL. The 
IDEEL underwent an extensive development process, contains the most QOL measures of 
these two questionnaires, and may offer the best assessment of DED’s effect on QOL for 
clinical trials. The OSDI, however, can be completed much more quickly than the IDEEL, is free 
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for use, and thus may be the more convenient option for use in the clinic. Other questionnaires 
(e.g. NEI-VFQ-25, TERTC-DEQ, etc.) can be used to assess QOL in dry eye patients but are 
extremely limited in this assessment due to a lack of QOL measures or a lack of validity and 
reliability testing.  This review highlights the need for further testing of these dry eye 
questionnaires.  
Finally, multiple studies continue to show DED’s deleterious effects on patients’ QOL, 
and PRO questionnaires remain one of the best ways to measure this disease-effect on a 
patient’s daily living.8 This review emphasizes the importance of including such QOL measures 
in future PRO questionnaires for DED. An increased emphasis on QOL in dry eye 
questionnaires will not only provide valuable outcome data for clinical trials but will also assist in 
the clinical treatment and management of DED.  
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APPENDIX B: Cognitive Interviewing Protocol and Template 
Cognitive Interviewing Protocol Summary 
In brief, I and another medical student examined the clinic schedule of two 
ophthalmologists here at the UNC ophthalmology clinic for potential patients with dry eye 
disease from December, 2012, to January, 2013. We subsequently recruited these patients in 
clinic, explained the research study, answered any questions, and then had the patients sign 
informed consent documents. We then administered both the UNC DEMS and OSDI to the 
participants. After they had completed the questionnaires, we then asked the patients multiple 
questions about the UNC DEMS using the process of cognitive interviewing. The basic template 
for our cognitive interviews is provided on the next page. The interviewer asked each patient all 
the questions in this template but would sometimes ask additional questions to clarify a patient 
response or to gather more information about a patient’s opinion of the questionnaires. On 
average, the interviews lasted 15-20 minutes. The project was approved by UNC’s IRB (study 
number 12-2089). 
 
  
31 
 
Cognitive Interviewing Template 
Did patient take both the DESSS scale and the validated questionnaire before this 
interview? YES        NO             If not please explain: 
_________________________________________________________________________ 
Scripted Introduction: Hello, my name is __________, and I am a medical student helping to 
develop a new questionnaire for dry eyes. If you don’t mind, I’m going to ask you a few 
questions about that questionnaire [show them the questionnaire they just completed]. I did not 
develop this questionnaire, and you are not going to hurt my feelings at all with anything you say 
about it. We want to make this questionnaire the best it can be for helping people like you, so 
feel free to say anything that comes to mind when answering my questions.  Do you have any 
questions? Let’s get started.  
 
1. What do you think the question is asking about? 
 
2. I asked you to use a 1 to 10 scale.  
a. Can you describe what you are thinking of when you think of a 1?  
b. And what about the 10—what are you thinking of? 
c. What about the middle? What are you thinking of when you think of the 5? 
 
3. People usually say the symptoms of dry eyes are pain, burning, grittiness, foreign body 
sensation/“feeling like something’s in your eye”, tearing, and sensitivity of light. I’d like to 
take each of these, and ask what they mean to you? 
a. First, let’s start with pain. How does pain from dry eyes feel to you? 
b. Next, let’s talk about burning. How does burning from dry eyes feel to you? 
c. Let’s move on to grittiness. How does grittiness from dry eyes feel to you? 
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d. Ok, now foreign body sensation/“feeling like something’s in your eye”. What does 
___(either term listed above) ___ caused by dry eyes feel like to you? 
e. How about tearing? How does tearing caused by dry eyes feel to you? 
f. Now our last symptom—sensitivity to light. How does sensitivity to light caused 
by dry eyes feel to you?  
g. Do you experience any other symptoms from dry eyes?____________________ 
How does __(previous answer)__ feel to you? 
 
4. In the questionnaire, we asked about how your dry eye symptoms affected your daily 
life. What does daily life mean to you? 
 
Follow-up: Can you give me an example of daily life? [NOTE: Interviewer, do NOT 
provide them an example; if they ask for one, say “anything that came to mind when I 
asked the question”] 
 
5. When you picked a number on the scale, were you thinking more about the dry eye 
symptoms, the effect on your daily life, or both? 
 
Follow-up: When you say __(previous answer)__, tell me what comes to mind. 
 
6. How do your dry eye symptoms affect your daily life?  
 
7. We gave examples to give you an idea of what the numbers on the scale might mean 
[can point out one or two examples if necessary]. Do you think the examples we gave 
match the numbers on the scale?  
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Follow-up: Can you think of any other examples for the numbers? 
 
[NOTE: This question was modified for patients 8-18 due to us removing the examples 
from specific numbers on the scale and placing the examples at the top of the page. 
Patients 8-18 were asked the following question: “We gave you some examples of daily 
living. Are there any other examples you can think of that we should include in this 
questionnaire?”] 
 
8. We used the words “mild” “moderately” and “severe” to describe your dry eye symptoms.  
a. Do you feel the word “mild” matches a 3-4 on the scale?  
b. Do you feel the word “moderately” matches a 5-6 on the scale? 
c. Do you feel the word “severe” matches a 7-8 on the scale?  
 
[NOTE: For the latter patients in this study, question 8c was modified to read as follows: 
“Do you feel the word ‘very bothersome’ matches a 7-8 on the scale?”] 
 
9. Similarly, we used the words “hardly” “sometimes” and “frequently” to describe how the 
symptoms may have affected your daily life.  
a. When the scale says “hardly affects your daily life” does that match a 3-4 on the 
scale?  
b. When the scale says “sometimes affects your daily life” does that match a 5-6 on 
the scale?  
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c. When the scale says “frequently affects your daily life” does that match a 7-8 on 
the scale?  
 
10. Does this scale let you say how good or bad your eyes are feeling?  
 
11. How easy or hard is it to remember how your dry eyes affected you in the past week? 
 
Follow-up: How do you remember this? 
 
12. Did the 10 point scale let you say enough about what you are feeling that you didn’t 
need to answer the other questions we gave you [show them OSDI] OR was answering 
the other questions helpful? 
 
13. Is there anything else we’ve forgotten or that you think we need to know to make this a 
good scale in describing your dry eye symptoms and the effect on your daily life? 
 
